FY 2027 Food and Drug Administration Budget Priorities for CDER, CBER and CDRH FY 2027 National Institutes of Health Budget Priorities Reauthorization of the Prescription Drug User Fee Act; PFUFA VIII Reauthorization of the Medical Device User Fee Act; MDUFA VI
Lobbyists:
CYNTHIA BENS — covered position: Staff, Representative Paul E. Kanjorski
Government entities lobbied:HOUSE OF REPRESENTATIVES; SENATE
HCR — Health Issues
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act S.2761/H.R.5269 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Implementation of Rural Health Transformation Program Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model [CMS-5546-P] Global Benchmark for Efficient Drug Pricing (GLOBE) Model [CMS-5545-P] Reclassification of Nucleic Acid-Based Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product; Proposed Amendment; Proposed Order; Request for Comments [Docket No. FDA-2025-N-4622] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Lobbyists:
CYNTHIA BENS — covered position: Staff, Representative Paul E. Kanjorski
Government entities lobbied:Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE
pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.